| Drug Name |
Perampanel |
| Drug ID |
BADD_D01733 |
| Description |
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™. |
| Indications and Usage |
Used in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. |
| Marketing Status |
approved |
| ATC Code |
N03AX22 |
| DrugBank ID |
DB08883
|
| KEGG ID |
D08964
|
| MeSH ID |
C551441
|
| PubChem ID |
9924495
|
| TTD Drug ID |
D0U3ED
|
| NDC Product Code |
11071-904; 47848-049; 50379-0020; 60510-609; 62856-280; 11071-906; 62856-276; 69616-274; 69616-278; 69616-280; 62856-272; 69616-282; 11071-907; 60510-604; 60510-608; 11071-902; 60510-606; 69616-290; 67835-0026; 62856-278; 62856-282; 62856-290; 69616-272; 11071-905; 62856-274; 69616-276; 11071-903; 60510-605; 60510-607 |
| UNII |
H821664NPK
|
| Synonyms |
perampanel | 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one | perampanel hydrate | perampanel hydrate (4:3) | E-2007 | E2007 | ER-155055-90 | Fycompa |
